| Literature DB >> 30333552 |
Khalid Al-Habsi1, David Jordan2, Ali Harb1, Tanya Laird1, Rongchang Yang1, Mark O'Dea1, Caroline Jacobson1, David W Miller1, Una Ryan1, Sam Abraham3.
Abstract
This study investigated faecal carriage and antimicrobial resistance (AMR) of Salmonella enterica recovered from rangeland goats. Faecal samples (n = 400) were collected at slaughter from four consignments of goats (n = 100 samples per consignment), each from one of four localities in Western Australia. Carriage of Salmonella spp. was detected in 106 samples (26.5%; 95% CI 22.4-31.0%). The rate of faecal carriage for each consignment ranged between 23-30%. PCR assays targeting the STM2755 and STM4497 genes revealed 84.9% (90/106) of the isolates were of serovar Typhimurium. Salmonella Chester (11/106, 10.4%) and S. Saintpaul (5/106, 4.7%) were characterised at invA and ompF genes. Antimicrobial susceptibility testing demonstrated that 84.0% of isolates were susceptible to all tested (n = 13) antimicrobials. Resistance was identified to azithromycin (14.2%), tetracycline (10.4%), ampicillin (5.7%), amoxicillin-clavulanate and cefoxitin (3.8%), trimethoprim/sulfamethoxazole (1.9%), gentamicin and streptomycin (0.9%). No isolate was resistant to four or more antimicrobials, or to critically important antimicrobials such as fluoroquinolones and extended spectrum cephalosporins. This is the first study reporting AMR in Salmonella isolates from Australian rangeland goats. The rate of detection of AMR was very low, some resistance to low-importance drugs was present in the Salmonella population, despite the absence of active selection pressure.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30333552 PMCID: PMC6193037 DOI: 10.1038/s41598-018-33220-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Map depicting locations of the stations from which goat consignments were sourced.
Breakpoints used for susceptibility testing of Salmonella species.
| Class | Agent | Range (mg/L) | nWTa | Clinical Breakpointb | |
|---|---|---|---|---|---|
| CS | CR | ||||
| Aminoglycosides | Gentamicin | 0.25–16 | 2 | ≤4 | >8 |
| Streptomycin | 2–64 | 16 | ≤32 | >32 | |
| β-lactam/β-lactam inhibitor combination | Amoxicillin-Clavulanate (2:1 ratio) | 1–32 | — | ≤8 | >16 |
| Cephems | Cefoxitin | 0.5–32 | 8 | ≤8 | >16 |
| Ceftiofur | 0.12–8 | 2 | — | — | |
| Ceftriaxone | 0.25–64 | — | ≤1 | ≥4 | |
| Fluoroquinolones | Ciprofloxacin | 0.015–4 | 0.06 | ≤0.06 | >0.5 |
| Quinolones | Nalidixic acid | 0.5–16 | — | — | — |
| Folate pathway inhibitors | Trimethoprim-Sulfamethoxazole (1:19) | 0.12–4 | 1 | ≤2 | >2 |
| Macrolides | Azithromycin | 0.12–16 | — | — | — |
| Penicillins | Ampicillin | 1–32 | 8 | ≤8 | >16 |
| Phenicols | Chloramphenicol | 2–32 | 16 | ≤8 | >16 |
| Tetracyclines | Tetracycline | 4–32 | 8 | ≤4 | >8 |
anWT = non-wild type [EUCAST epidemiological cut-off values (mg/L) (ECOFF)].
bCLSI VETO1S,(CLSI, 2015) or M100S(CLSI, 2016) breakpoints (mg/L), CS = Clinically-sensitive; CI = Clinically-Intermediate (between CS and CR, not shown); CR = Clinically-resistant.
“—” Not defined.
Percent of rangeland goats (n = 400) with Salmonella enterica detected in faeces at slaughter in Western Australia showing breakdown by origin of consignment and serovar detected.
| Consignment | Percent of goats with | |||
|---|---|---|---|---|
| All serovars | Serovars | |||
| Overall ( | 26.5 (22.4–31.0) | 22.5 (18.6–26.8) | 2.8 (1.5–4.7) | 1.25 (0.5–2.7) |
| Carnarvon ( | 28 (19.9–37.3) | 24 (16.5–33.0) | 2 (0.4–6.3) | 2 (0.4–6.3) |
| Shark Bay ( | 30 (21.7–39.5) | 23 (15.6–31.9) | 5 (1.9–10.6) | 2 (0.4–6.3) |
| Yalgoo ( | 23 (15.6–31.9) | 21 (13.9–29.7) | 2 (0.4–6.3) | 0 (0.0–2.5) |
| Wooramel ( | 25 (17.3–34.1) | 22 (14.8–30.8) | 2 (0.4–6.3) | 1 (0.1–4.6) |
Antimicrobial resistance.
Distribution of MICs and resistance among Salmonella isolates (n = 106) from faecal samples collected from rangeland goats at slaughter in Western Australia.
| Antimicrobial | 0.016 | 0.03 | 0.06 | 0.13 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | % nWT (95% CI) | % CR 95% CI |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amoxicillin-Clavulanate | — | — | — | — | — | — | 89.6 | 1.9 | 3.8 | 0.9 | 3.8 | x | 3.8 (1–9.4) | ||
| Ampicillin | — | — | — | — | — | — | 83 | 9.4 | 1.9 | 0.9 | 0.9 | 3.8 | 5.7 (2.1–11.9) | 4.7 (1.5–10.7) | |
| Azithromycin | — | — | — | 2.8 | 47.2 | 35.8 | 14.2 | — | x | 14.2 (8.1–22.3) | |||||
| Cefoxitin | — | — | — | — | — | 0.9 | 51.9 | 38.7 | 4.7 | 0.9 | 2.8 | 3.8 (1–9.4) | 2.8 (0.6–8) | ||
| Ceftiofur | — | — | — | 9.4 | 85.8 | 4.7 | — | — | — | 0 (0–3.4) | — | ||||
| Chloramphenicol | — | — | — | — | — | — | — | 4.7 | 88.7 | 6.6 | — | 0 (0–3.4) | 0 (0–3.4) | ||
| Ciprofloxacin | 22.6 | 73.6 | 3.8 | — | — | — | — | 0 (0–3.4) | 0 (0–3.4) | ||||||
| Ceftriaxone | — | — | — | — | 95.3 | 4.7 | x | 0 (0–3.4) | |||||||
| Gentamicin | — | — | — | — | 11.3 | 75.5 | 12.3 | 0.9 | — | — | 0.9 (0–5.1) | 0 (0–3.4) | |||
| Naladixic Acid | — | — | — | — | — | 4.7 | 82.1 | 11.3 | 1.9 | — | x | — | |||
| Streptomycin | — | — | — | — | — | — | — | 0.9 | 13.2 | 56.6 | 28.3 | 0.9 | 0.9 (0–5.1) | — | |
| Tetracycline | — | — | — | — | — | — | — | — | 89.6 | 10.4 | 10.4 (5.3–17.8) | 10.4 (5.3–17.8) | |||
| Trimethoprim/Sulfamethoxazole | — | — | — | 89.6 | 7.5 | 0.9 | 0.9 | 0.9 | — | — | — | 1.9 (0.2–6.6) | 0.9 (0–5.1) |
nWT, non-wild type; CR, clinical resistance; “x” No data presented for this drug due to lack of wild, susceptible and clinical breakpoints. Cells not denoted as ‘—’ indicate MIC range available for each agent available on the Sensititre CMV3AGNF card. MICs > than highest concentration available are indicated in the shaded region. Thin vertical lines indicate EUCAST ECOFF values and Thick vertical lines indicate CLSI resistant breakpoints.